SCHEMBL3236003

SCHEMBL3236003

Cc1c(Br)cc(C(=O)NC(c2ccccc2)C2(N(C)C)CCCC2)c(C)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
SLC6A9 P48067 8/20 0.39
POLB P06746 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
USP2 O75604 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
CYP3A4 P08684 1/20 0.35
HTT P42858 1/20 0.35
ACP1 P24666 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3242235 0.85 ALDH1A1 (0.43) MEN1KMT2ACYP1A2CYP2C19SLC6A9
SCHEMBL3244640 0.83 SLC6A9 (0.42) KMT2ASLC6A9ALDH1A1HPGDMAPT
SCHEMBL3237287 0.81 SLC6A9 (0.45) CYP1A2CYP2C19SLC6A9HPGDSLC6A5
SCHEMBL3240639 0.81 SLC6A9 (0.38) MEN1KMT2ASLC6A9HPGDSLC6A5
SCHEMBL3232935 0.81 SLC6A9 (0.47) KMT2ACYP1A2CYP2C19SLC6A9MAPT
SCHEMBL3243792 0.80 POLB (0.47) MEN1KMT2ASLC6A9POLBHSD17B10
SCHEMBL3239525 0.80 UTS2R (0.43) KMT2ASLC6A9POLBL3MBTL1ALDH1A1
SCHEMBL3237710 0.79 ALDH1A1 (0.42) MEN1KMT2ASLC6A9ALDH1A1HPGD
SCHEMBL3234800 0.79 SLC6A9 (0.51) SLC6A9L3MBTL1SLC6A5
SCHEMBL3237802 0.79 SLC6A9 (0.48) MEN1KMT2ACYP1A2CYP2C19SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
WO-2006067423-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 MEN1 2501/4885KMT2A 1871/4885CYP1A2 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.